Shil Patel

Shil Patel has a strong background in the pharmaceutical industry with extensive experience in various leadership roles.

Shil currently holds the position of Vice President, Translational Pharmacology at Ratio Therapeutics.

Prior to their current role, Shil served as Vice President at Codiak BioSciences, where they led the Imaging and Exploratory Research team, utilizing non-invasive imaging techniques to drive pipeline assets and assess the company's platform in new therapeutic areas.

Before joining Codiak BioSciences, Shil worked at Eisai US as Senior Director from 2016 to 2018.

Shil also had a long tenure at Biogen Idec, where they served as Director and played a key role in establishing and leading a preclinical imaging group across various programs in Neurology, Hemophilia, and Immunobiology.

Shil's early career was primarily at Merck and Merck and Co Inc., where they held the position of Research Fellow. During their time at Merck, they were involved in preclinical drug discovery, including the development and optimization of binding assays and functional screens, molecular biology techniques, and the identification and validation of molecular targets for neuropsychiatric disorders.

Shil Patel completed a BSc in Biochemistry from Royal Holloway, University of London in 1986. Shil then pursued an MSc in Biochemical Pharmacology from the University of Southampton for the academic year 1986-1987. Finally, they earned a PhD in Neuroscience from the University of Hertfordshire between 1990 and 1997.